# US 12,599,607 B2 · Pharmaceutical compositions comprising timolol > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,599,607 B2 - Document ID: US12599607B2 - Status: Granted - Kind: B2 - Application number: 18/778,226 - Filed: 2024-07-19 - Published: 2024-11-07 - Granted: 2026-04-14 - Earliest claimed: 2018-03-28 - Assignees: Novaliq GmbH - Applicants: Novaliq GmbH - Inventors: Frank Löscher; Sonja Krösser; Diana Strehl; Bernhard Hauptmeier; Kirsten Eickhoff - Web page: https://patentgrep.com/patent/US12599607B2 ## CPC - A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol - A61K 9/0048: {Eye, e.g. artificial tears} - A61K 9/08: Solutions {(composition of solutions A61K47/00)} - A61K 9/10: Dispersions; Emulsions - A61P 27/06: Antiglaucoma agents or miotics - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention relates to pharmaceutical composition comprising the beta 1 (β1)-receptor blocker timolol and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention may be useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith. ## Claims ### Claim 1 A pharmaceutical composition consisting of particles of timolol maleate and a liquid vehicle; wherein the particles consist of the timolol maleate, and wherein the particles are suspended in the liquid vehicle; wherein the liquid vehicle consists essentially of 1-perfluorohexyloctane and optionally a co-solvent; wherein at least 90% of the suspended particles of the timolol maleate have a size of not more than about 20 μm; wherein the concentration of the timolol maleate in the pharmaceutical composition corresponds to about 0.5% (w/v) of timolol, measured as the free base; and wherein the composition is formulated for topical ophthalmic administration. ### Claim 2 (depends on 1) The pharmaceutical composition according to claim 1, wherein the liquid vehicle further comprises the co-solvent. ### Claim 3 (depends on 1) The pharmaceutical composition according to claim 1, wherein the liquid vehicle consists essentially of the 1-perfluorohexyloctane. ### Claim 4 (depends on 1) The pharmaceutical composition of claim 1, wherein at least about 90% of the suspended particles of the timolol maleate have a size of not more than about 15 μm. ### Claim 5 (depends on 1) The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition provides a dose volume per eye of from about 10 to about 12 μl which comprises about 55 μg timolol, measured as the free base. ### Claim 6 (depends on 1) A method for the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, in a patient in need thereof, comprising administering to said patient a pharmaceutical composition according to claim 1, wherein the composition is topically administered to the eye of the patient at a single dose of about 55 μg timolol, measured as the free base, per eye. ### Claim 7 (depends on 6) The method according to claim 6, wherein the pharmaceutical composition is administered to the eye of the patient up to four times daily. ### Claim 8 (depends on 6) The method according to claim 6, wherein the pharmaceutical composition is administered to the eye of the patient two times daily or once daily. ### Claim 9 (depends on 6) The method according to claim 6, wherein the pharmaceutical composition is administered in a dose volume per eye of from about 10 to about 12 μl. ### Claim 10 (depends on 6) The method according to claim 6, wherein the liquid vehicle further comprises the co-solvent. ### Claim 11 (depends on 6) The method according to claim 6, wherein the liquid vehicle essentially consists of the 1-perfluorohexyloctane. ### Claim 12 (depends on 6) The method according to claim 6, wherein the pharmaceutical composition is topically administered to the eye of the patient at a single dose of 55 μg timolol, measured as the free base, per eye. ### Claim 13 (depends on 6) The method according to claim 6, wherein the pharmaceutical composition is administered in a dose volume per eye of from about 11 μl. ### Claim 14 (depends on 11) The method according to claim 11, wherein the pharmaceutical composition is topically administered one time daily to the eye of the patient at a single dose of 55 μg timolol, measured as the free base, per eye. ### Claim 15 (depends on 11) The method according to claim 11, wherein the pharmaceutical composition is topically administered two times daily to the eye of the patient at a single dose of 11 μl per eye. ### Claim 16 (depends on 6) The method according to claim 6, wherein the pharmaceutical composition is free of water and free of a preservative. ### Claim 17 (depends on 6) The method according to claim 6, wherein at least about 90% of the suspended particles of timolol maleate have a size of not more than about 10 μm. ### Claim 18 (depends on 6) The method according to claim 6, wherein at least about 90% of the suspended particles of timolol maleate have a size of not more than about 15 μm after three weeks of storage at room temperature. ### Claim 19 (depends on 1) The composition according to claim 1, wherein the liquid vehicle consists essentially of at least 99.5% (w/w) 1-perfluorohexyloctane, with respect to the total weight of the liquid vehicle. ### Claim 20 (depends on 16) The method according to claim 16, wherein the pharmaceutical composition is a preservative-free ophthalmic composition, that is provided in a microbiologically stable multi-dose or single dose format. ### Claim 21 (depends on 16) The method according to claim 16, wherein the method comprises the step of redispersing the particles of timolol maleate by gently shaking the container holding the composition before topically administering the composition to the eye.